anecortave rinn ænəˈkɔːrteɪv novel angiogenesis inhibitor used treatment exudative wet form agerelated macular degeneration although similar chemical structure corticosteroid hydrocortisone acetate possesses glucocorticoid approved marketed alcon anecortave acetate depot suspension trade name retaane development reported since addition treating wetform agerelated macular degeneration aka neovascular agerelated macular degeneration also evaluated potential therapy dryform age related macular degeneration well reducing intraocular pressure eyes ocular steroid injectionrelated anecortave synthesized addition synthesized anecortave acetate derived cortisol reducing hydroxyl cortisol double bond carbons addition acetate group carbon results molecule glucocorticoid mineralocorticoid retaane mg anecortave acetate depot suspension manufactured alcon inc fast track designated product also drug fda pilot continuous marketing application cma program often enrolls drugs brought market indication significant unmet medical need allowed retaane file fda using rolling new drug application allows specific units chemistry manufacturing controls cmc preclinical clinical unit nda reviewed completed instead one large document allows fda review unit within six months submission alcon first filed cmc unit preclinical clinical units alcon inc announced received approval letter nda retaanecitation needed alcon got letter approval retaane indication treat wet agerelated macular degeneration amd final approval would require completion additional clinical study result supported anecortave acetate riskreduction trial aart study looked efficacy retaane reduce progression dry form amd wet form ended alcon announced terminating development anecortave acetate prevention developing sightthreatening choroidal neovascularization secondary agerelated macular alcon announced end drugs development reducing intraocular pressure associated source needed currently anecortave acetate market made therapeutic source needed retaane depot delivered via posterior juxtascleral depot pjd delivers drug onto sclera near macula delivery method allows decreased risk intraocular infection well decreased risk detachment retina delivery method advantageous retaane compared angiogenesis inhibitors used similar indications delivered every six months compared nine twelve times year allows increased patient httpsenwikipediaorgwikianecortaveacetate